Disease Domain | Count |
---|---|
Hemic and Lymphatic Diseases | 1 |
Immune System Diseases | 1 |
Nervous System Diseases | 1 |
Neoplasms | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Top 5 Target | Count |
---|---|
PARP(Poly (ADP-Ribose) polymerase) | 1 |
Target |
Mechanism PARP inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Purinergic receptor modulators |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NOS2 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date19 Aug 2016 |
Sponsor / Collaborator |
Start Date01 Sep 2015 |
Sponsor / Collaborator |
Start Date01 Aug 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
PJ-34 (Tel Aviv University) ( PARP ) | Stroke More | Preclinical |
INO-4885 ( Reactive oxygen species ) | Asthma More | Discontinued |
INO-1271 ( Purinergic receptor ) | Glaucoma More | Discontinued |
INO-2002 ( NKRF ) | Rheumatoid Arthritis More | Discontinued |
Guanidinoethyldisulfide Bicarbonate ( NOS2 ) | Gingival Diseases More | Discontinued |